Pitt Street Research | Stock research
Prescient Therapeutics.png

Prescient Therapeutics

Prescient Therapeutics is a Melbourne-based drug developer focused on cancer, with several platforms and products in its portfolio. Prescient Therapeutics' lead compound is a small molecule called PTX-100, which is potentially a significant future treatment for T-Cell Lymphoma. The company also has two cell therapy platform technologies: OmniCAR, which allows next-generation CAR-T (Chimeric Antigen Receptor T-cell therapy) products to be developed, and CellPryme, which allows enhances adoptive cell therapy performance.

Prescient Therapeutics (ASX:PTX)

 

Prescient Therapeutics is a Melbourne-based drug developer focused on cancer, with several platforms and products in its portfolio. Prescient Therapeutics' lead compound is a small molecule called PTX-100, which is potentially a significant future treatment for T-Cell Lymphoma. The company also has two cell therapy platform technologies: OmniCAR, which allows next-generation CAR-T (Chimeric Antigen Receptor T-cell therapy) products to be developed, and CellPryme, which allows enhances adoptive cell therapy performance.